Sign in with Google
bullish
Dr. Reddy's Laboratories (DRRD IN): Q4FY23 Result- Sequential Decline in Key Parameters
488 Views12 May 2023 08:27
SUMMARY
- Dr. Reddy's Laboratories (DRRD IN) announced mixed Q4FY23 result, with revenue beating consensus and net profit missing expectations. Both revenue and net profit grew YoY but declined sequentially.
- North America grew 27% YoY (but declined 17% QoQ) to INR25.3B, driven by new product launches, growing market share in certain existing products, and favorable Fx movement.
- Revenue from India business increased 32% YoY and 14% QoQ to INR12.8B, driven by favorable price variance, new product launches including acquired/in-licensed products, and non-core brand divestments.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »Top Unpaywalled Insights
More »- [IO Technicals 2025/22] Bearish Momentum Strengthens
- Texas Power Play: Grid Sovereignty, Bitcoin, and the Future of AI
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
- Curator's Cut: Korea's Value, CATL's Charge and Copper's Surge
- New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Dr. Reddy's Laboratories (DRRD IN): US and Europe Drive Highest Ever Sales in Q3; Profit Surges 11%14 Feb 2024
- Dr. Reddy's Laboratories (DRRD IN): Highest Ever Sales and Profit in Q2; Good Show in Key Markets30 Oct 2023
- Dr. Reddy's Laboratories (DRRD IN): Q1FY24 Result- US Business Shines; PAT Jumps 18%28 Jul 2023
- Dr. Reddy's Laboratories (DRRD IN): Q4FY23 Result- Sequential Decline in Key Parameters12 May 2023
- Dr. Reddy's Laboratories (DRRD IN): New Acquisition to Bolster US Generic Product Portfolio28 Feb 2023
- Dr. Reddy's Laboratories (DRRD IN): Q3FY23 Results- Sequential Improvement Supported by US29 Jan 2023
- Dr. Reddy's Laboratories (DRRD IN): New Launch Aided Q2 Result; Rich Pipeline Lends Visibility05 Nov 2022
x